title: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
abstract: OBJECTIVE
  The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma.
  
  
  METHODS
  Thirty patients were entered onto the study from April 2005 through October 2006. Paclitaxel was administered intravenously as a 60-minute infusion at a dose of 80 mg/m(2) on days 1, 8, and 15 of a 4-week cycle. The primary end point was the nonprogression rate after two cycles.
  
  
  RESULTS
  The progression-free survival rates after 2 and 4 months were 74% and 45%, respectively. With a median follow-up of 8 months, the median time to progression was 4 months and the median overall survival was 8 months. The progression-free survival rate was similar in patients pretreated with chemotherapy and in chemotherapy-naïve patients (77% v 71%). Three patients with locally advanced breast angiosarcoma presented partial response, which enabled a secondary curative-intent surgery with complete histologic response in two cases. One toxic death occurred as a result of a thrombocytopenia episode. Six patients presented with grade 3 toxicities and one patient presented with a grade 4 toxicity. Anemia and fatigue were the most frequently reported toxicities.
  
  
  CONCLUSIONS
  Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.
authors.affiliation: Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France. n-penel@o-lambret.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Penel
authors.forename: Binh Nguyen
authors.initials: BN
authors.lastname: Bui
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.forename: Didier
authors.initials: D
authors.lastname: Cupissol
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Sophie
authors.initials: S
authors.lastname: Piperno-Neumann
authors.forename: Pierre
authors.initials: P
authors.lastname: Kerbrat
authors.forename: Charles
authors.initials: C
authors.lastname: Fournier
authors.forename: Sophie
authors.initials: S
authors.lastname: Taieb
authors.forename: Marta
authors.initials: M
authors.lastname: Jimenez
authors.forename: Nicolas
authors.initials: N
authors.lastname: Isambert
authors.forename: Frédéric
authors.initials: F
authors.lastname: Peyrade
authors.forename: Christine
authors.initials: C
authors.lastname: Chevreau
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bompas
authors.forename: Etienne G C
authors.initials: EG
authors.lastname: Brain
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005602:France / Q000453:epidemiology; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel